Grandeur Peak Global Advisors LLC Has $4.93 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Grandeur Peak Global Advisors LLC raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 20.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 63,420 shares of the medical device company's stock after purchasing an additional 10,795 shares during the period. Grandeur Peak Global Advisors LLC's holdings in DexCom were worth $4,932,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Versant Capital Management Inc purchased a new position in shares of DexCom in the 4th quarter worth $25,000. Private Trust Co. NA increased its stake in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC lifted its stake in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,009 shares of company stock valued at $8,044,178. Corporate insiders own 0.30% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research firms recently commented on DXCM. Citigroup raised their price target on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Mizuho assumed coverage on DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target for the company. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Finally, Morgan Stanley increased their target price on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $99.00.

DexCom Stock Up 2.7 %

Shares of DXCM stock traded up $1.84 during trading hours on Tuesday, hitting $69.23. 4,613,566 shares of the company were exchanged, compared to its average volume of 4,201,448. The stock has a market capitalization of $27.15 billion, a price-to-earnings ratio of 48.41, a P/E/G ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a one year low of $57.52 and a one year high of $139.24. The business's 50-day simple moving average is $76.49 and its two-hundred day simple moving average is $76.68. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.